On Tuesday, Abbott Laboratories (NYSE: ABT) opened higher 0.58% from the last session, before settling in for the closing price of $129.93. Price fluctuations for ABT have ranged from $107.11 to $141.23 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 29.98% over the last five years. Company’s average yearly earnings per share was noted 10.21% at the time writing. With a float of $1.73 billion, this company’s outstanding shares have now reached $1.74 billion.
The firm has a total of 114000 workers. Let’s measure their productivity. In terms of profitability, gross margin is 56.14%, operating margin of 17.54%, and the pretax margin is 18.32%.
Abbott Laboratories (ABT) Breakdown of a Key Holders of the stock
A key investor’s attitude towards the stock of the Medical Devices industry is another important factor to consider. The insider ownership of Abbott Laboratories is 0.67%, while institutional ownership is 80.17%. The most recent insider transaction that took place on Apr 30 ’25, was worth 337,116. In this transaction Director of this company sold 2,600 shares at a rate of $129.66, taking the stock ownership to the 34,058 shares. Before that another transaction happened on Apr 30 ’25, when Company’s Director proposed sale 2,600 for $129.66, making the entire transaction worth $337,116.
Abbott Laboratories (ABT) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of 1.49 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 10.21% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 10.31% during the next five years compared to 29.98% growth over the previous five years of trading.
Abbott Laboratories (NYSE: ABT) Trading Performance Indicators
Check out the current performance indicators for Abbott Laboratories (ABT). In the past quarter, the stock posted a quick ratio of 1.30. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 5.28. Likewise, its price to free cash flow for the trailing twelve months is 33.57.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 8.00, a number that is poised to hit 1.30 in the next quarter and is forecasted to reach 5.67 in one year’s time.
Technical Analysis of Abbott Laboratories (ABT)
Analysing the last 5-days average volume posted by the [Abbott Laboratories, ABT], we can find that recorded value of 5.71 million was lower than the volume posted last year of 6.93 million. As of the previous 9 days, the stock’s Stochastic %D was 82.70%.
During the past 100 days, Abbott Laboratories’s (ABT) raw stochastic average was set at 56.61%, which indicates a significant decrease from 93.25% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 2.90 in the past 14 days, which was higher than the 2.77 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $131.70, while its 200-day Moving Average is $125.91.
